Trials Offered by a Specific Doctor

HERBERT IRVING COMPREHENSIVE CANCER CENTER
Investigator
Mark Heaney, MD, PhD
Email
mlh2192@cumc.columbia.edu

Mark Heaney received his undergraduate education at Harvard and graduate education at the University of Virginia where he received an M.D. and a Ph.D. in microbiology. After Internal Medicine residency at SUNY Stony Brook, he had fellowship training in Hematology and Medical Oncology at Memorial Sloan-Kettering Cancer Center. Dr. Heaney subsequently joined the faculty at Memorial Sloan-Kettering Cancer Center. As a member of the Leukemia Service for nearly 20 years, Dr. Heaney continued laboratory research, initially studying the cell surface receptors that govern white blood cell development and leukemia cell growth. More recently, he has focused on metabolic differences between leukemia cells and normal cells that can provide insight into how leukemias behave in the individual patient and how they respond to treatment. His finding that vitamin C has the potential to blunt the beneficial effects of chemotherapy has been widely cited.

Dr. Heaney has also been an active clinical investigator. He has been the Principal Investigator of many clinical trials that have aimed at developing new treatments for leukemia. In particular, he has focused on new treatments of the myeloproliferative neoplasms, primary myelofibrosis, polycythemia vera and essential thrombocythemia, but has also studied new treatments for chronic myeloid leukemia, mastocytosis and Langerhans cell histiocytosis in keeping with his clinical expertise in rare blood cancers.

Dr. Heaney joined the faculty at CUMC in January, 2013. He has continued his commitment to caring for patients with blood cancers, developing new treatments including cutting edge clinical trials, and laboratory research that concentrates on translating discoveries from the bench to the bedside. He also renewed his investment in medical education, becoming Director of the Hematology and Medical Oncology Fellowship Program in 2014.


Clinical Studies Managed By Dr. Heaney:
More InfoTitleSponsorIRB Number
Details[CLOSED] A study for patients with Thrombocytopenia and Primary Myelofibrosis using study drug pacritinibCTI BioPharmaAAAP1153
Details[CLOSED] A study for patients with myelofibrosis using study drug PF-04449913PfizerAAAO5760
Details[CLOSED] A study for patients with myeloproliferative disorders using study drug momelotinibGileadAAAQ5062
Details[CLOSED] A study for patients with high-risk Myelofibrosis (MF) using study drug imetelstatJanssen Research & Development, LLCAAAQ6800
DetailsA study for patients with myelofibrosis (bone marrow disorder) using study drug INCB050465Incyte CorporationAAAR0403
Details[CLOSED] Study of Effectiveness of Ruxolitinib in combination with Decitabine in Patients with Myeloproliferative Neoplasms (MPN)Myeloproliferative Disorders Research ConsortiumAAAO0959
DetailsStudy of Rigosertib in Patients with Myelodysplastic Syndrome (MDS)Onconova Therapeutics Inc.AAAP9823
DetailsStudy of Experimental Drug in Patients with Elevated Thrombocythemia (Too Many Platelets, Leading to Abnormal Blood Clotting or Bleeding)Incyte CorporationAAAR3247
DetailsStudy of Experimental Drug Therapy in Patients with Polycythemia Vera (PV)F. Hoffmann- La Roche Ltd.AAAR4907
DetailsA Study of DCC-2618 in Patients with Advanced MalignanciesDeciphera Pharmaceuticals, LLCAAAR7574
DetailsStudy of CPI-0610 in Patients with MyelofibrosisConstellation PharmaceuticalsAAAR8502
DetailsBiomarker Study of Philadelphia Chromosome Negative Myeloproliferative Neoplasms (MPN)Myeloproliferative Disorders - Research Consortium MPD - RCAAAO1856
DetailsDetermining Changing in Cardiovascular and Metabolic Risks in Patients with Chronic Myeloid LeukemiaBristol-Myers SquibbAAAR8507
DetailsStudy of Avapritinib (BLU-285) in Patients with Advanced Systemic MastocytosisBlueprint Medicines CorporationAAAR9514